Recurrent translocations, t(8;21) or inv(16), in core binding factor acute myeloid leukemia (CBF-AML) are amenable to monitoring for minimal residual disease (MRD) with reverse transcriptase polymerase chain reaction (RTPCR). Despite a favorable prognosis, disease relapse remains the single cause of treatment failure in CBF-AML. Fusion products of these translocations recruit epigenetic silencing complexes resulting in hematopoietic maturation arrest. We hypothesized that maintenance therapy with hypomethylating agents (HMA), including decitabine (DAC) and azacitidine (AZA) after induction/consolidation, can be used for MRD elimination to ultimately prolong relapse free survival. Real-time quantitative (RTPCR) trends were reviewed in 23 patients (median age 53 years) with CBF-AML that received HMA therapy following induction/consolidation with fludarabine, cytarabine, and G-CSF (FLAG) with low dose gemtuzumab or idarubicin (NCT00801489).
| I N T R O D U C T I O N
The presence of translocation t(8;21) (q22;q22) or inversion inv (16) (p13q22)/t(16;16) characterizes core binding factor acute myeloid leukemia (CBF-AML).
1 CBF-AML, representing 15% of all acute myeloid leukemia, has a favorable prognosis when treated with intermediate to high dose cytarabine-based induction and consolidation regimens. [2] [3] [4] However, disease relapse remains as a major cause of treatment failure, despite a cure rate of >65% with chemotherapy alone. 5 Real-time quantitative (RTPCR) techniques allow for the detection and quantification of leukemia-associated genes to measure minimal residual disease (MRD). RTPCR based MRD monitoring provides prognostic information and guides postremission therapy including allogeneic stem cell transplantation (SCT) in CBF-AML. 5 Several prior studies have
shown that routine monitoring of MRD is important in CBF-AML to monitor for relapse and provide dynamic risk stratification while on treatment, with several efforts trying to quantitatively define the MRD level that might signify overt relapse and necessitate salvage therapy. [5] [6] [7] [8] [9] [10] [11] [12] [13] In addition to persistent elevation of RTPCR transcript, identification of concomitant mutations along with t(8;21) and inv(16) also portend a higher risk of relapse. 14, 15 Mutations in c-KIT have been shown to shorten relapse free survival (RFS) and event free survival (EFS) in t (8;21) patients, reduced overall survival (OS) in inv(16) patients, and when present with persistent MRD and a high white blood cell count, shorter RFS in all CBF-AML patients. 14-16 FLT3-ITD mutations have inhibitors. 17 Along with evaluation of MRD, additional mutation data was obtained for further investigation in this analysis.
One unanswered question is what strategy to adopt when a patient is in morphological remission but has persistent molecular MRD or in patients who had truncated high dose consolidation because of adverse events. Hypermethylation of certain genes while patients are in remission has been associated with an increased likelihood of relapse in AML. 5, 18, 19 Promoter hypermethylation of tumor suppressors is also frequently seen in CBF-AML. 20, 21 Hypomethylating agents including decitabine (DAC) and azacitidine (AZA) can potentially reverse such epigenetic silencing. 22, 23 Several studies have recently explored HMA maintenance therapy in AML. 24, 25 Though significant survival improvement has not been shown with this strategy, some clinical benefit has been observed, and the use of MRD directed HMA maintenance has not been extensively explored. 25 We hypothesized that maintenance therapy with hypomethylating agents, such as DAC and AZA, can be used to target residual low-level PCR positivity and eliminate minimal residual disease (MRD) to ultimately prolong relapse free survival in CBF-AML. 26, 27 The sensitivity of detection for transcript RTPCR at the time of this analysis was between 1 in 10 000 and 1 in 100 000.
| M E T H O D S
Patient characteristics and outcomes were obtained from chart review and departmental database. Mutations in KIT, FLT3ITD, FLT3D835, and RAS genes were tested at baseline. In addition, most patients were evaluated for NPM1, TP53, IDH1, and IDH2 mutations at baseline.
| Objectives
The primary objectives of this analysis were to monitor MRD status by serial RTPCR response to HMA therapy after the completion of induction/consolidation and to determine RTPCR baseline values and trends that predict for a higher likelihood of achieving durable remission on HMA maintenance. 
| Patient selection

| Treatment regimen
The 
| Mutation analysis
Mutation analysis was carried out in exons 8 and 17 in KIT gene, in codons 12, 14, and 61 in NRAS and KRAS genes using PCR-based DNA sequencing methods, and for internal tandem duplications (ITD) or D835 mutations in FLT3 gene according to published methods. 29 
| Statistical analysis
Median RTPCR values between HMA responders and HMA failures were compared using the nonparametric Mann-Whitney test. OS was calculated using Kaplan-Meier estimates, and survival estimates were compared using the log-rank test. RAGON ET AL.
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As of last follow-up, all six patients who started HMA with undetectable MRD remained MRD negative (RTPCR < 0.01) and in remission, and 8 out of the total 23 patients continued on maintenance therapy.
Median follow-up was 11.3 months (range, 2.9-67.7).
| Mutational status
Of the five patients failing HMA, 4 [inv (16) 
| DISCUSSION
Despite a favorable prognosis, relapse occurs in 20-25% of the patients with CBF and is usually preceded by a period of increased RTPCR transcripts. Strategies to intervene if a patient does not achieve appropriate reduction in RTPCR levels or shows rising trends postcompletion of planned induction/consolidation may avert full-blown relapses. SCT is one such option, but donor availability and patient related factors including age, performance status, and organ dysfunction may be potential barriers to timely and safe SCT. 30 The importance of MRD monitoring in CBF-AML has been well defined. old were published. 24 Though preliminary data and case reports of using DAC maintenance in CBF-AML were promising, maintenance DAC following complete remission after induction therapy did not provide clinical benefit in either the non CBF-AML or CBF-AML cohorts; the authors reported the study was not powered to identify small differences in survival, and minimal residual disease was not addressed. 24 Boumber and colleagues explored DAC maintenance versus conventional care in AML patients in complete remission and found that DAC maintenance was safe, feasible, and led to fewer relapses; however, the trial was not powered to provide more significant conclusions. 25 In
Boumber's study, MRD was assessed and associated with EFS and OS in a multivariate Cox regression model. Only 1 patient had CBF-AML, and that patient received conventional care and went on to relapse. Co-existing mutations were identified in patients including RAS, KIT, and FLT3. In the HMA failure group, 80% of patients had a coexisting mutation. For those who responded to HMA maintenance, 67% carried a concomitant mutation. Co-existing RAS mutations were identified in highest frequency, followed by KIT, then FLT3 mutations. This is concordant with the typical distribution of co-existing mutations in CBF-AML. 31 With the small number of patients in this analysis, the impact of co-existing mutations on the efficacy of HMA maintenance therapy cannot be adequately determined. In future studies, it will be important to monitor for co-existing mutations as a majority of patients with persistent MRD in our analysis had concomitant mutations. Only one of six patients (17%) who proceeded to HMA maintenance without detectable MRD had a co-existing mutation, suggesting that mutation burden might contribute to persistent MRD in CBF-AML.
There are many limitations to this analysis. The small sample size and exploratory nature of this retrospective analysis limit the conclusions that can be made. An important limitation in this analysis is that levels of MRD required for initiation of HMA therapy were not predefined. Subsequently, observations regarding appropriate levels of MRD that would warrant HMA maintenance can be made, but a well-designed clinical trial with predefined MRD levels will provide improved guidance in utilizing maintenance therapy in CBF-AML.
Another possible limitation is that peripheral blood and bone marrow were used in MRD assessments for patients in this analysis. The study was not powered to recognize differences between the two sample types, but others studies suggest that either can be used for MRD assessment. 32 An additional important limitation identified is that this analysis includes patients who proceeded to maintenance therapy without detectable MRD, and although these patients have successfully remained in remission, it is difficult to attribute the success completely to HMA maintenance.
Despite the limitations of this analysis, CBF-AML patients with low levels of RTPCR (between 0.01 and 0.05) at the conclusion of induction/consolidation chemotherapy derived the most benefit from maintenance HMA, particularly those with a reduction in the RTPCR within the first two cycles of HMA therapy. We propose this population be explored further in future studies of HMA maintenance in CBF-AML.
